TheraRadar
Data updated: May 26, 2026

DEPACON (valproate sodium)

CNS Approved 1996-12-30
Jump to: Indications Approvals Trials Competitors Safety Patents
2
Indications
--
Phase 3 Trials
29
Years on Market

Details

Status
Discontinued
First Approved
1996-12-30
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

AbbVie
Active Ingredient: VALPROATE SODIUM

DEPACON Approval History

1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
33 FDA actions from 1996 to 2020 · 1 indication expansions
May 2020 SUPPL
Label · Labeling
FDA Letter Label
Nov 2019 SUPPL
Label · Labeling
FDA Letter Label
Feb 2019 SUPPL
Label · Labeling
FDA Letter Label

What DEPACON Treats

2 FDA approvals

Originally approved for its first indication in 1996 . Covers 2 distinct patient populations.

  • Other (2)
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT06081283 results posted 23-0157 Ph 4 terminated Antiseizure Medication in Seizure Networks at Early Acute Brain Injury
NCT04698525 results posted 74-19 Ph 3 completed Comparative Study Between Valproate and Memantine in the Prophylactic Management of Episodic Migraine.
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DEPACON FDA Label Details

Track DEPACON with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

FDA Approval: NDA020593 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.